Back to search
FDAFDA · Food and drugs·Recall number D-1350-2022

SUSTANGO (Pendenadril Tytrate Blend) Capsules, 400 mg, 10-count blisters per carton, Formulated by: Male FX Labs, Bangor, ME, ASIN X0024468I9.

Published August 10, 2022 · Recall initiated: July 21, 2022

Summary

FDA records drug Class I recall D-1350-2022, published August 10, 2022 and initiated July 21, 2022. Recalling firm: Ultra Supplement LLC; Status: Terminated; Reported quantity: 750 cartons; Lot: Lot DAP272109, Exp: 4/1/2026. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Marketed Without an Approved NDA/ANDA: Analytical testing showed the presence of tadalafil.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Ultra Supplement LLC
Distributor
Product was distributed nationwide in the USA via Amazon Marketplace on www.amazon.com.
Lot
Lot DAP272109, Exp: 4/1/2026
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was SUSTANGO (Pendenadril Tytrate Blend) Capsules, 400 mg, 10-count blisters per carton, Formulated by: Male FX Labs, Bangor, ME, ASIN X0024468I9. recalled?

Yes. FDA published recall D-1350-2022 on August 10, 2022. Reported hazard: Marketed Without an Approved NDA/ANDA: Analytical testing showed the presence of tadalafil.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release